Physician profile
Eric M Robach
NPI 1306828355
$2,227.56
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $992 · 2020: $838 · 2021: $348 · 2022: $49.13.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $712.15 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $402.14 | 2019-2022 | |
| Lilly USA, LLC | $261.69 | 2019-2021 | |
| Amgen INC. | $215.77 | 2019-2021 | |
| Pfizer INC. | $113.28 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $96.18 | 2020-2021 | |
| Amarin Pharma, INC. | $93.70 | 2019-2020 | |
| Abbvie INC. | $57.78 | 2020-2022 | |
| Allergan, INC. | $47.10 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.86 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $39.11 | 2019 | |
| Merck Sharp & Dohme LLC | $38.88 | 2019-2020 | |
| Astellas Pharma US INC | $35.68 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $16.69 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.04 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $14.09 | 2019 | |
| Genentech USA, INC. | $12.25 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.17 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Robach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.